Evaluating Immune Checkpoint Inhibition Response Biomarkers |
0.75 |
06/15/2023 - 12:00am to 06/15/2024 - 12:00am |
Clinical Scenario #1: Applying Biomarkers in Risk Stratification of Localized Prostate Cancer |
0.75 |
06/15/2023 - 12:00am to 06/15/2024 - 12:00am |
Management of Toxicities of BTK Inhibitors in B-Cell Malignancies |
0.75 |
12/01/2023 - 12:00am to 12/01/2024 - 12:00am |
Clinical Scenario #2: Applying Biomarkers in Breast Cancer |
0.75 |
06/15/2023 - 12:00am to 06/15/2024 - 12:00am |
Clinical Scenario #3: Applying Biomarkers in Central Nervous System Cancers |
0.75 |
06/15/2023 - 12:00am to 06/15/2024 - 12:00am |
Chronic Myeloid Leukemia/Myelofibrosis: TKI Therapy and Toxicity Management |
0.75 |
12/01/2023 - 12:00am to 12/01/2024 - 12:00am |
Clinical Scenario #4: Applying Biomarkers in Non-Small Cell Lung Cancer |
0.75 |
06/15/2023 - 12:00am to 06/15/2024 - 12:00am |
Clinical Scenario #5: Applying Biomarkers in Biliary Tract Cancers |
0.75 |
06/15/2023 - 12:00am to 06/15/2024 - 12:00am |
Prophylactic Vaccines/Immunizations for Cancer Patients |
0.75 |
08/04/2022 - 12:00am to 08/04/2024 - 12:00am |
Psychotherapeutic Strategies and Pharmacotherapy Options for Addressing Distress in Cancer Patients |
0.75 |
08/04/2022 - 12:00am to 08/04/2024 - 12:00am |
Case Studies in the Management of Leukemia |
0.75 |
12/01/2023 - 12:00am to 12/01/2024 - 12:00am |
Immunotherapy in Hepatocellular Carcinoma: Improving the Treatment Paradigm Within Community Practice |
1.00 |
12/19/2023 - 12:00am to 12/19/2024 - 12:00am |
NCCN Guidelines® Insights - Survivorship, Version 1.2023 |
1.00 |
08/10/2023 - 12:00am to 08/10/2024 - 12:00am |
What is Biomarker Testing, and Why Is It Important? |
1.00 |
06/15/2023 - 12:00am to 06/15/2024 - 12:00am |
Archived Monthly Oncology Tumor Boards: Treatment of Deficient Mismatch Repair or Microsatellite Instability-High (dMMR/MSI-H) Colorectal Cancer |
1.00 |
08/18/2023 - 12:00am to 08/18/2024 - 12:00am |